Questions Remain After BioNTech’s Lead Cancer Asset’s Phase III Study Hold
The company and partner OncoC4 remain tight-lipped on what’s behind the partial hold in the NSCLC study of gotistobart, which could impact BioNTech’s nascent oncology plans.
The company and partner OncoC4 remain tight-lipped on what’s behind the partial hold in the NSCLC study of gotistobart, which could impact BioNTech’s nascent oncology plans.